



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 01 Aug 2022 (#30)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov) or [www.sun.ac.za/RDSfunding](http://www.sun.ac.za/RDSfunding) (current & archive).

**Confirm your intent to apply ASAP, but not later than 60 days before the submission date.**

Tygerberg Campus: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) • Stellenbosch Campus [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za)

## Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

## Important Notices

[NOT-GM-22-041](#) Notice for the National Institute of General Medical Sciences ([NIGMS](#)) Grant Writing Webinar Series for Institutions Building Research and Research Training Capacity. NIGMS will host an informational webinar series for faculty and sponsored programs/research development personnel from institutions building research and research training capacity. During the webinars, suggestions will be shared for navigating the process of seeking NIH funding. [Registration](#) is required to attend.

[NOT-HL-22-037](#) Notice of National Heart, Lung, and Blood Institute ([NHLBI](#)) Participation in [PAR-21-252](#) "Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed)" NHLBI is interested in applications that promote the prevention and treatment of heart, lung, blood, or sleep (HLBS) disorders in low- and middle-income countries (LMICs). Examples of HLBS diseases and disorders include, but are not limited to, hypertension, obesity, rheumatic heart disease, chronic obstructive lung diseases, asthma, and sickle cell disease. Training across the spectrum of research disciplines is encouraged, from basic biomedical, behavioral and social science to clinical and applied sciences, including translational and implementation science that emphasizes the resources, context and needs of multiple stakeholders in local settings. Training on research skills, research design and methodology, ethics, data management and analysis, grant writing, manuscript writing, scientific presentations and research administration should be included in the career development plan. Mentors should have strong track records in HLBS research and training early stage investigators for independent research careers. The mentored research career development experience should lead to an independently-funded research career on HLBS diseases and disorders across the lifespan and build scientific capacity for HLBS research at LMIC institutions.

[NOT-HL-22-038](#) Notice of National Heart, Lung, and Blood Institute ([NHLBI](#)) Participation in [PAR-21-251](#) "Emerging Global Leader Award (K43 Independent Clinical Trial Required)" NHLBI is interested in applications that promote the prevention and treatment of heart, lung, blood, or sleep (HLBS) disorders in low- and middle-income countries (LMICs).

Examples of HLBS diseases and disorders include, but are not limited to, hypertension, obesity, rheumatic heart disease, chronic obstructive lung diseases, asthma, and sickle cell disease. Training across the spectrum of research disciplines is encouraged, from basic biomedical, behavioral and social science to clinical and applied sciences, including translational and implementation science that emphasizes the resources, context and needs of multiple stakeholders in local settings. Training on research skills, research design and methodology, ethics, data management and analysis, grant writing, manuscript writing, scientific presentations and research administration should be included in the career development plan. Mentors should have strong track records in HLBS research and training early stage investigators for independent research careers. The mentored research career development experience should lead to an independently-funded research career on HLBS diseases and disorders across the lifespan and build scientific capacity for HLBS research at LMIC institutions.

**[NOT-HD-22-030](#) Notice of Extension of [PAR-20-299](#), "Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)"** New Expiration Date: 12 April 2023. Application Due Dates: 9 December 2022, 11 April 2023.

**[NOT-HD-22-031](#) Notice of Extension of [PAR-20-300](#), "Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional)"** New Expiration Date: 12 April, 2023. Application Due Dates: 9 December 2022, 11 April 2023.

**[NOT-NS-22-120](#) Notice of Correction to Announcement Type for "[PAR-22-142](#): NINDS Exploratory Clinical Trials (UG3/UH3 Clinical Trial Required)"**. The purpose of this Notice is to correct the Announcement Type in [PAR-22-142](#) "NINDS Exploratory Clinical Trials (UG3/UH3 Clinical Trial Required)". This Funding Opportunity Announcement (FOA) erroneously listed the Announcement type as "New". This has been corrected to show [PAR-22-142](#) is a reissue of "[PAR-21-236](#)".

**[NOT-MH-22-280](#) Notice of Intent to Publish a Funding Opportunity Announcement for Clinical Studies of Mental Illness (Collaborative R01 Clinical Trial Optional)**. The National Institute of Mental Health ([NIMH](#)) intends to publish a Funding Opportunity Announcement (FOA) to solicit applications for collaborative clinical studies not involving treatment development, efficacy, or effectiveness trials. The FOA will be a reissue of [PAR-19-297](#), "Clinical Studies of Mental Illness (Collaborative R01 Clinical Trial Optional)". Consistent with the objectives of [PAR-19-297](#), applicants will be expected to propose collaborative projects for two or more sites. Primary areas of focus include mental health genetics, biomarker studies, and studies of mental illnesses (e.g., psychopathology, neurodevelopmental trajectories of psychopathology) including when associated with HIV/AIDS. Collaborating studies will share a specific protocol across the sites. In studies with a large number of sites, it is expected that one site will be submitted as a coordinating R01 for data management and/or other centralized administration. For a linked set of collaborative R01s, each application will have its own Program Director/Principal Investigator (PD/PI). The collaborative R01 program provides a mechanism for cross-R01 coordination, quality control, database management, statistical analysis, and reporting. First Estimated Application Due Date: 5 October 2022.

**[NOT-NS-23-009](#) Notice of Intent to Publish a Funding Opportunity Announcement for HEAL Initiative Integrated Basic and Clinical Team-based Research in Pain (RM1 Clinical Trial Optional)**. The National Institutes of Health (NIH) Helping to End Addiction Long-termSM (HEAL) Initiative intends to publish a new Funding Opportunity Announcement (FOA) to solicit applications for multi-PI team-based integrated research efforts for pursuing bold, impactful, and challenging research in basic and clinical pain domains to understand the biology of specific human pain conditions as well as pain associated with diverse diseases/disorders, including mechanistic underpinning of heterogeneity and stratification of patients with specific pain conditions and co-morbidities. First Estimated Application Due Date: 11 November 2022.

## Notice of Special Interest (NOSI)

**[NOT-AT-22-027](#) Promoting Mechanistic Research on Therapeutic and Other Biological Properties of Minor Cannabinoids and Terpenes**. This NOSI is being issued by the National Center for Complementary and Integrative Health ([NCCIH](#)) with participation from multiple NIH Institutes, Centers, and Offices (ICOs). This NOSI aims to promote mechanistic research of therapeutic benefits of minor cannabinoids and terpenes in the cannabis plant. It intends to

support highly innovative basic and/or mechanistic studies in appropriate model organisms and/or human subjects aiming to investigate the impact of minor cannabinoids and terpenes on mechanisms underlying their therapeutic effects. Preclinical studies of combinations of minor cannabinoids with terpenes or other natural products that may enhance their therapeutic benefits and/or abate unwanted effects are encouraged. The mechanisms and processes underlying potential contribution of minor cannabinoids and terpenes to symptoms relief and functional restoration may be very broad encompassing different pathological conditions and diseases. This NOSI encourages interdisciplinary collaborations among experts from multiple fields, such as pharmacologists, chemists, physicists, physiologists, neuroscientists, psychologists, endocrinologists, immunologists, geneticists, behavioral scientists, clinicians, or others in relevant areas of inquiry. This Notice applies to applications with due dates on or after 5 October 2022 and subsequent receipt dates through 5 June 2024. Submit applications for this Notice using one of the FOAs listed or any reissues of these announcements through the expiration date of this notice.

**[NOT-OD-22-185](#) Notice of Special Interest (NOSI): Administrative Supplements to Support Extramural Collaborators for Notified Applicants for the Bench-to-Bedside and Back Program (BtB) (Clinical Trial Optional).**

Aiming to improve human health, the NIH Bench-to-Bedside and Back Program (BtB) Program ([https://ocr.od.nih.gov/btb/btb\\_program.html](https://ocr.od.nih.gov/btb/btb_program.html)) supports innovative small/pilot research projects designed to translate basic scientific findings into therapeutic interventions for patients and to increase understanding of important clinical observations of disease processes. It promotes robust multi-directional collaborations among laboratory ("bench") and patient-focused ("bedside") investigators. Through the NIH BtB Program, this funding opportunity will invite two-year administrative supplement applications for collaborations between the NIH intramural research investigators, who conduct translational and clinical research and extramural NIH recipients. Every project must include an NIH intramural investigator who is responsible for submitting the BtB Letter of Intent (LOI) and application online (Proposal Central; PC; <https://proposalcentral.com/>). **This NOSI is intended for the extramural collaborators of awarded Bench to Bedside (BtB) proposals.**

## Funding Opportunity Announcements (FOA)

### 1. Biology of Bladder Cancer (R01 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-22-218](#)

**Type:** R01

**Application Due Date:** 5 October 2022 through to 5 June 2025. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This FOA encourages applications that investigate the biology and underlying mechanisms of bladder cancer. Bladder cancer is a significant health problem both in the United States and globally. Because of the high incidence and frequent tumor recurrence, bladder cancer exacts an outsized medical burden. While recent progress has been made in the molecular profiling of bladder cancers and identification of mutated genes, relatively little is known regarding the molecular mechanisms driving initiation, progression and malignancy of bladder cancer. Furthermore, our understanding of the biological processes of the normal bladder at the molecular, cell and organ levels is limited. Fundamental knowledge of how molecular and cellular functions of the bladder are altered in cancer will aid our understanding of bladder cancer biology and contribute to the future development of new interventions.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years. Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application

### 2. Biology of Bladder Cancer (R21 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-22-219](#)

**Type:** R21

**Application Due Date:** 16 October 2022 through to June 16, 2025. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This FOA encourages applications that investigate the biology and underlying mechanisms of bladder cancer. Bladder cancer is a significant health problem both in the United States and globally. Because of the high incidence and frequent tumor recurrence, bladder cancer exacts an outsized medical burden. While recent progress has been made in the molecular profiling of bladder cancers and identification of mutated genes, relatively little is known regarding the molecular mechanisms driving initiation, progression and malignancy of bladder cancer. Furthermore, our understanding of the biological processes of the normal bladder at the molecular, cell and organ levels is limited. Fundamental knowledge of how molecular and cellular functions of the bladder are altered in cancer will aid our understanding of bladder cancer biology and contribute to the future development of new interventions.

**Budget:** The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

**3. Cellular and Molecular Mechanisms of Prion-Like Aggregate Seeding, Propagation, and Neurotoxicity in AD/ADRD (R01 Clinical Trial Not Allowed)**

**Letter of Intent: 30 days prior to the application due date**

**Hyperlink: [PAR-23-023](#)**

**Type: R01**

**Application Due Date:** 24 October 2022. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This purpose of this FOA is to solicit applications that propose mechanistic studies in animal, cell culture, and/or human tissue models to elucidate the mechanisms by which prion-like processes in AD/ADRD are initiated, propagated, and ultimately lead to neurodegeneration and circuit dysfunction.

**Budget:** NINDS intends to commit \$3,750,000 in FY 2023 to fund up to five awards. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are limited to \$500,000 direct costs/year and need to reflect the actual needs of the proposed project. Each award can be up to five years in duration. The scope of the proposed project should determine the project period. The maximum project period is five years.

**4. Academic Development of a Training Program for Good Laboratory Practices in High Containment Environments (U24) Clinical Trials Not Allowed**

**Letter of Intent: 30 days prior to the application due date**

**Hyperlink: [RFA-FD-23-002](#)**

**Type: U24**

**Application Due Date:** 3 October 2022, by 11:59 PM Eastern Time.

**Funding Opportunity Announcement:** U.S. Food and Drug Administration ([FDA](#)) seeks to continue a robust, collaborative, and educational program using problem-based learning techniques designed to bring researchers and regulators together to educate each other on the challenges related to these issues and to identify solutions that are acceptable from both scientific and regulatory perspectives. This program consists of the continued development and implementation of a certified, academic training course for instruction in Good Laboratory Practices (GLP) in a Biosafety Level (BSL) 4 High Containment Environment.

**Budget:** The number of awards is contingent upon FDA appropriations and the submission of a sufficient number of meritorious applications. Award(s) will provide one (1) year of support and include future recommended support for FOUR (4) additional year(s) contingent upon annual appropriations, availability of funding and satisfactory recipient performance. FDA/OC intends to commit up to \$400,000 for fiscal year 2023 to fund (1) ONE award. The scope of the proposed project should determine the project period. The maximum project period is five (5) years.

Research Development and Support Division (RDSD),  
Faculty of Medicine and Health Sciences  
5<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.  
Enquiries: *Christa*  
e: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | t: +27 21 938 9838

Division for Research Development (DRD)  
Stellenbosch Campus  
2041 Krottoa Building, Ryneveld Street  
Enquiries: *Lizél*  
e: [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | t: +27 21 808 2105